Cumberland And Vanderbilt Announce Phase 2a Clinical Trial Of Ifetroban Met Primary Endpoint Demonstrating Safety And Tolerability Of Ifetroban In Patients With High-Risk Solid Tumors

Loading news article.

Cumberland And Vanderbilt Announce Phase 2a Clinical Trial Of Ifetroban Met Primary Endpoint Demonstrating Safety And Tolerability Of Ifetroban In Patients With High-Risk Solid Tumors | WAPE

Cumberland And Vanderbilt Announce Phase 2a Clinical Trial Of Ifetroban Met Primary Endpoint Demonstrating Safety And Tolerability Of Ifetroban In Patients With High-Risk Solid Tumors

Article summary

Related companies

Comments —